Investors'' Presentation on unaudited Standalone and Consolidated Financial Results for the first quarter ended June 30, 2026

Concord Biotech Ltd has released its unaudited standalone and consolidated financial results for the first quarter ended June 30, 2026, showing a broad-based growth across all product categories, with exports growing by ~46% for Q1FY27 (Y-o-Y). The company has also witnessed an increase in wallet share among existing customers, addition of new products, and a robust product pipeline. The financial highlights include a revenue growth of +26%, EBITDA growth of +34%, and PAT growth of +31%.